Topical Retinoid Compositions

Dr. Reddy's Laboratories, Ltd.
Refused App No 201747045067 Chemical

Patent information

IP India · live record
Application number
201747045067
Filing date
14 December 2017
Status
Refused
Publication number
16/2018
Publication type
INA
Invention field
Chemical

Abstract

The present application relates to topical compositions. In particular the present application relates to a topical composition comprising retinoid as active agent and pharmaceutically acceptable excipient(s) and a process of preparing such compositions. Further the present application relates to method of using topical compositions for the treatment of skin disorders such as acne rosacea psoriasis etc.

Applicants

1
India
DR. REDDY'S LABORATORIES, LTD. 8-2-337, Road No. 3 Hyderabad, Telangana 500034, India

Inventors

4
U.S.A.
KADAVILLI, Sateesh412 Fox Run Drive Plainsboro, New Jersey 08536, United States of America
India
BANKAR, Manish M.Plot No 1253, Vaishali Nagar Nagpur, Maharashtra 440017, India
India
DOLAI, Sujit KumarAt-Kukudakhandi District Ganjam, Odisha 761100, India
U.S.A.
OKUMU, Franklin162 Franklin Street Morristown, New Jersey 07960, United States of America

Specification

Show full textCollapse

What is claimed is: 1. A topical composition comprising: a) a retinoid compound; b) at least one foaming agent; c) at least one anti-irritant; and d) one or more dermatologically acceptable excipients, wherein said anti-irritant is selected from polyhydroxy acids in the range of from about 0.01% to about 3% of the total weight of the composition. 2. The topical composition of claim 1, wherein the polyhydroxy acid is gluconolactone. 3. The topical composition of claim 1, and further comprising tocofersolan. 4. The topical composition of claim 1, wherein the foaming agent is selected from disodium laureth sulfosuccinate, cocobetaine, sodium lauryl sarcosinate, and sodium lauryl sulfate, or mixtures thereof. 5. The topical composition of claim 1, wherein a retinoid compound is selected from tretinoin, isotretinoin, acitretin, tazarotene, and adapalene. 6. The topical composition of claim 5, wherein the retinoid compound is tazarotene. 7. The topical composition of claim 1, wherein the polyhydroxy acid is gluconolactone; the foaming agent is selected from disodium laureth sulfosuccinate, cocobetaine, sodium lauryl sarcosinate, and sodium lauryl sulfate, or mixtures thereof; and the retinoid compound is selected from tretinoin, isotretinoin, acitretin, tazarotene, and adapalene. 8. The topical composition of claim 7, wherein the retinoid compound is tazarotene. 9. The topical composition of claim 7 or 8, further comprising tocofersolan. 10. A method of treating skin disorders by topically applying to a skin in need thereof, a topical composition according to any one of claims 1-8, comprising the steps of a) shaking the composition; b) topically applying the wash composition to the affected area of the skin for a period of about 0 seconds to about 15 minutes; and c) rinsing-off said composition from the affected area with water or a suitable solvent.

11. The method according to claim 10, wherein the composition is rinsed-off within 5 minutes. 12. The method according to claim 10, wherein the skin disorder is selected from acne vulgaris, rosacea, atopic dermatitis, skin wrinkles, facial mottle, hyperpigmentation, hypopigmentation, photo aging, papule, pustule, psoriasis, nodulocystic acne lesion and lentigo. 13. An aqueous-based topical composition comprising: a) a retinoid compound; b) at least one foaming agent; c) at least one anti-irritant; and d) one or more dermatologically acceptable excipients, wherein said anti-irritant is selected from polyhydroxy acids in the range of from about 0.01% to about 3% of the total weight of the composition, and wherein said topical composition comprises at least about 60% of water based on final weight of the composition. 14. The aqueous-based topical composition of claim 13, and further comprising tocofersolan. 15. The aqueous-based topical composition of claim 10, wherein the polyhydroxy acid is gluconolactone. 16. The aqueous-based topical composition of claim 10, wherein the foaming agent is selected from disodium laureth sulfosuccinate, cocobetaine, sodium lauryl sarcosinate, and sodium lauryl sulfate, or mixtures thereof. 17. The aqueous-based topical composition of claim 10, wherein a retinoid compound is selected from tretinoin, isotretinoin, acitretin, tazarotene, and adapalene. 18. An aqueous-based topical composition comprising: a) from about 0.01% to about 1% of tazarotene or pharmaceutically acceptable salts, esters thereof; b) from about 0.1 % to about 7% of foaming agents selected from disodium laureth sulfosuccinate, cocobetaine, sodium lauryl sarcosinate, and sodium lauryl sulfate, or mixtures thereof; c) from about 0.01% to about 3% of an anti-irritant selected from polyhydroxy acids or tocofersolan or mixtures thereof; and d) one or more dermatologically acceptable excipients, wherein said topical composition comprises at least about 60% of water based on final weight of the composition. 19. The aqueous-based topical composition of claim 18, wherein tazarotene is in micronized form.

20. The aqueous-based topical composition of claim 18, comprising tazarotene in suspended form. 21. A process of preparing topical composition comprising steps of: 1) preparing a retinoid-containing dispersion comprising: mixing a retinoid compound with a foaming agent and water to prepare a dispersion; 2) preparing an emulsion by mixing an aqueous phase and an oil phase under homogenization; 3) preparing the composition by mixing retinoid-containing dispersion and emulsion together under homogenization; and 4) adjusting the pH of the retinoid-containing topical composition using a suitable pH adjusting agent, in the range of about 4 to about 7, wherein said emulsion of step 2 is pre-neutralized using a suitable pH adjusting agent, in the range of about 4 to about 7. 22. A method of treating acne comprising: administering retinoid-containing topical composition of claim 1,13 and 18 to a patient in need thereof, wherein said composition administers an effective amount of retinoid compound(s) to the skin.

Documents

Sign in to open
Orders
Section
Application documents
1 201747045067-STATEMENT OF UNDERTAKING (FORM 3) [14-12-2017(online)].pdf 14 Dec 2017
2 201747045067-POWER OF AUTHORITY [14-12-2017(online)].pdf 14 Dec 2017
3 201747045067-FORM 1 [14-12-2017(online)].pdf 14 Dec 2017
4 201747045067-DRAWINGS [14-12-2017(online)].pdf 14 Dec 2017
5 201747045067-DECLARATION OF INVENTORSHIP (FORM 5) [14-12-2017(online)].pdf 14 Dec 2017
6 201747045067-COMPLETE SPECIFICATION [14-12-2017(online)].pdf 14 Dec 2017
7 201747045067.pdf 24 Mar 2018
8 201747045067-FORM 3 [29-03-2018(online)].pdf 29 Mar 2018
9 201747045067-Proof of Right (MANDATORY) [14-06-2018(online)].pdf 14 Jun 2018
10 201747045067-RELEVANT DOCUMENTS [05-07-2018(online)].pdf 05 Jul 2018
11 201747045067-RELEVANT DOCUMENTS [05-07-2018(online)]-1.pdf 05 Jul 2018
12 201747045067-Proof of Right (MANDATORY) [05-07-2018(online)].pdf 05 Jul 2018
13 201747045067-PETITION UNDER RULE 138 [05-07-2018(online)].pdf 05 Jul 2018
14 201747045067-Changing Name-Nationality-Address For Service [05-07-2018(online)].pdf 05 Jul 2018
15 Correspondence by Agent _Form 1_11-07-2018.pdf 11 Jul 2018
16 201747045067-RELEVANT DOCUMENTS [21-12-2018(online)].pdf 21 Dec 2018
17 201747045067-FORM 13 [21-12-2018(online)].pdf 21 Dec 2018
18 201747045067-AMENDED DOCUMENTS [21-12-2018(online)].pdf 21 Dec 2018
19 201747045067-FORM 3 [05-04-2019(online)].pdf 05 Apr 2019
20 201747045067-FORM 18 [08-04-2019(online)].pdf 08 Apr 2019
21 201747045067-FORM 3 [16-09-2019(online)].pdf 16 Sep 2019
22 201747045067-FER.pdf 24 Jan 2020
23 201747045067-FORM 3 [16-03-2020(online)].pdf 16 Mar 2020
24 201747045067-OTHERS [09-06-2020(online)].pdf 09 Jun 2020
25 201747045067-FER_SER_REPLY [09-06-2020(online)].pdf 09 Jun 2020
26 201747045067-DRAWING [09-06-2020(online)].pdf 09 Jun 2020
27 201747045067-COMPLETE SPECIFICATION [09-06-2020(online)].pdf 09 Jun 2020
28 201747045067-CLAIMS [09-06-2020(online)].pdf 09 Jun 2020
29 201747045067-FORM 3 [16-09-2020(online)].pdf 16 Sep 2020
30 201747045067-US(14)-HearingNotice-(HearingDate-03-12-2021).pdf 03 Nov 2021
Search strategy
1201747045067searchreport_23-01-2020.pdf